Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience

Combining cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors with endocrine therapies in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in the first and second lines has emerged as optimal treatment strategy and has implications rel...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Irina V. Kolyadina, Inna P. Ganshina, Svetlana V. Kuzmicheva, Asiiat I. Tekeeva, James D. Kolokolov, Mikhail V. Volkonskii, Irina V. Poddubnaya
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2020
Materias:	advanced breast cancer hormonal therapy with cdk 4/6 inhibitors hormone resistance eribulin chemotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/b5ffcd19c09e4753ada4d68dd2290140
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b5ffcd19c09e4753ada4d68dd2290140
record_format	dspace
spelling	oai:doaj.org-article:b5ffcd19c09e4753ada4d68dd22901402021-11-30T17:03:34ZProspects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience1815-14341815-144210.26442/18151434.2020.2.200212https://doaj.org/article/b5ffcd19c09e4753ada4d68dd22901402020-07-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/34960/23375https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Combining cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors with endocrine therapies in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in the first and second lines has emerged as optimal treatment strategy and has implications related to clinical efficacy, rapid clinical response and manageable tolerability. However, approximately one in five women has progression during the first year, we have to make efforts to choose the treatments for hormone receptor-positive breast cancer. Potential treatment options include prospective chemotherapy drug eribulin, its efficacy has been demonstrated in various biological subtypes of metastatic breast cancer in patients pretreated with anthracyclines and taxanes. Data from EMPOWER study evaluating the use of eribulin in female patients with hormone positive HER2-negative metastatic breast cancer who received CDK 4/6 inhibitor therapy showed promising results. In the cohort eribulin was prescribed according to the FDA indications in the USA after at least three prior regimens with a prior anthracycline and a taxane overall response rate was 26.7%, clinical benefit rate was 54.1%, median progressive-free survival was not reached and 6-month progressive-free survival rates was 70.4%. Eribulin demonstrated a manageable tolerability profile, adverse event rates were similar to those in clinical trials and other observational studies. In this paper we present the analysis from Russia of five cases of luminal HER2-negative breast cancer who had progression after CDK 4/6 inhibitor therapy. All patients had visceral metastases, one of them had brain metastases. Eribulin was used according to prescribing information in Russia, in metastatic settings in patients pretreated with anthracyclines and taxanes in the second chemotherapy line (3 patients) and in the third line (2 patients). Four patients achieved stable disease, one patient had partial response. Duration of eribulin treatment response was from 8 to 22 months. Eribulin appeared to be well-tolerated, dose reduction was not noted. Data from EMPOWER (USA) and the first treatment results from Russia demonstrated eribulin may be a potential treatment option in hormone-positive breast cancer following prior CDK 4/6i therapy for disease control and to preserve quality of life.Irina V. KolyadinaInna P. GanshinaSvetlana V. KuzmichevaAsiiat I. TekeevaJames D. KolokolovMikhail V. VolkonskiiIrina V. PoddubnayaIP Habib O.N.articleadvanced breast cancerhormonal therapy with cdk 4/6 inhibitorshormone resistanceeribulin chemotherapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 22, Iss 2, Pp 98-103 (2020)
institution	DOAJ
collection	DOAJ
language	RU
topic	advanced breast cancer hormonal therapy with cdk 4/6 inhibitors hormone resistance eribulin chemotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	advanced breast cancer hormonal therapy with cdk 4/6 inhibitors hormone resistance eribulin chemotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Irina V. Kolyadina Inna P. Ganshina Svetlana V. Kuzmicheva Asiiat I. Tekeeva James D. Kolokolov Mikhail V. Volkonskii Irina V. Poddubnaya Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
description	Combining cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors with endocrine therapies in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in the first and second lines has emerged as optimal treatment strategy and has implications related to clinical efficacy, rapid clinical response and manageable tolerability. However, approximately one in five women has progression during the first year, we have to make efforts to choose the treatments for hormone receptor-positive breast cancer. Potential treatment options include prospective chemotherapy drug eribulin, its efficacy has been demonstrated in various biological subtypes of metastatic breast cancer in patients pretreated with anthracyclines and taxanes. Data from EMPOWER study evaluating the use of eribulin in female patients with hormone positive HER2-negative metastatic breast cancer who received CDK 4/6 inhibitor therapy showed promising results. In the cohort eribulin was prescribed according to the FDA indications in the USA after at least three prior regimens with a prior anthracycline and a taxane overall response rate was 26.7%, clinical benefit rate was 54.1%, median progressive-free survival was not reached and 6-month progressive-free survival rates was 70.4%. Eribulin demonstrated a manageable tolerability profile, adverse event rates were similar to those in clinical trials and other observational studies. In this paper we present the analysis from Russia of five cases of luminal HER2-negative breast cancer who had progression after CDK 4/6 inhibitor therapy. All patients had visceral metastases, one of them had brain metastases. Eribulin was used according to prescribing information in Russia, in metastatic settings in patients pretreated with anthracyclines and taxanes in the second chemotherapy line (3 patients) and in the third line (2 patients). Four patients achieved stable disease, one patient had partial response. Duration of eribulin treatment response was from 8 to 22 months. Eribulin appeared to be well-tolerated, dose reduction was not noted. Data from EMPOWER (USA) and the first treatment results from Russia demonstrated eribulin may be a potential treatment option in hormone-positive breast cancer following prior CDK 4/6i therapy for disease control and to preserve quality of life.
format	article
author	Irina V. Kolyadina Inna P. Ganshina Svetlana V. Kuzmicheva Asiiat I. Tekeeva James D. Kolokolov Mikhail V. Volkonskii Irina V. Poddubnaya
author_facet	Irina V. Kolyadina Inna P. Ganshina Svetlana V. Kuzmicheva Asiiat I. Tekeeva James D. Kolokolov Mikhail V. Volkonskii Irina V. Poddubnaya
author_sort	Irina V. Kolyadina
title	Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
title_short	Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
title_full	Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
title_fullStr	Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
title_full_unstemmed	Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
title_sort	prospects of eribulin administration for patients with hr-positive her2-negative metastatic breast cancer after progression on cdk4/6 inhibitors: theoretical background and first experience
publisher	IP Habib O.N.
publishDate	2020
url	https://doaj.org/article/b5ffcd19c09e4753ada4d68dd2290140
work_keys_str_mv	AT irinavkolyadina prospectsoferibulinadministrationforpatientswithhrpositiveher2negativemetastaticbreastcancerafterprogressiononcdk46inhibitorstheoreticalbackgroundandfirstexperience AT innapganshina prospectsoferibulinadministrationforpatientswithhrpositiveher2negativemetastaticbreastcancerafterprogressiononcdk46inhibitorstheoreticalbackgroundandfirstexperience AT svetlanavkuzmicheva prospectsoferibulinadministrationforpatientswithhrpositiveher2negativemetastaticbreastcancerafterprogressiononcdk46inhibitorstheoreticalbackgroundandfirstexperience AT asiiatitekeeva prospectsoferibulinadministrationforpatientswithhrpositiveher2negativemetastaticbreastcancerafterprogressiononcdk46inhibitorstheoreticalbackgroundandfirstexperience AT jamesdkolokolov prospectsoferibulinadministrationforpatientswithhrpositiveher2negativemetastaticbreastcancerafterprogressiononcdk46inhibitorstheoreticalbackgroundandfirstexperience AT mikhailvvolkonskii prospectsoferibulinadministrationforpatientswithhrpositiveher2negativemetastaticbreastcancerafterprogressiononcdk46inhibitorstheoreticalbackgroundandfirstexperience AT irinavpoddubnaya prospectsoferibulinadministrationforpatientswithhrpositiveher2negativemetastaticbreastcancerafterprogressiononcdk46inhibitorstheoreticalbackgroundandfirstexperience
_version_	1718406403393060864

Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience

Ejemplares similares